Mersana shows that B7-H4 expression matters
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
